According to the startup, the project has been several years in development, culminating in its recent public announcement of a successful seed funding round of $1.2m (€1m).
Further to this, the biotech stated that it is currently finalizing an additional $5m round with institutional investors.
Zenerchi is based in Salt Lake City, US, and Ho Chi Minh City, Vietnam – and aims to create a ‘4D human body simulator, 3D/VR/AR visualization and AI cloud platform.’
When asked what the plans are for the capital raised, Bryan Brandenburg, the company’s co-founder, chief scientific officer, and CEO, told us that the funds will be used to develop the company’s cloud-based SimViz AI solutions – set to be released next year.
The investment will also support business development to establish two or three more strategic partners.
Brandenburg explained that the biotech has “already signed a major partnership for Asia with one of the most significant consumer companies in China that will be announced in the next 30 days.”
In addition, the company has signed a partnership with an unnamed scientific institution, which will be announced in the next 60 days.
When asked what the potential utilization of the platform could look like in pharmaceutical research, Brandenburg described how the technology could be used to complement US Food and Drug Administration clinical trials by “testing on simulated patients,” or to run “current physiology simulations in real time with 3D/VR/AR.”
Zenerchi is set to launch its first public-facing tech implementation next year with an AI lab.
“We are projecting $40m in revenue within 18 months based on currently signed partnerships,” Brandenburg added, on further plans for the business. “We are already working with some of the top physiology simulations from the world's most prestigious universities.”
